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ABSTRACT 
Background: African Americans have both a higher incidence of prostate cancer and greater 
disease-specific mortality compared with non-Hispanic whites.  Historically, the investigation of 
the contribution of rare genetic variants to prostate cancer in African American men has been 
hampered by low participation in large genetic studies, particularly those focused on early-onset 
and familial disease.  
Methods:  We sequenced 160 genes purported to be involved in carcinogenic pathways in 
germline DNA samples collected from 96 African American men diagnosed with early-onset 
prostate cancer (≤55 years at diagnosis).  REVEL software was used to determine the pathogenic 
potential of observed missense variants. 
Results:  We observed 3 protein-truncating mutations, one in BRCA2 and 2 in BRIP1 in three 
African American men diagnosed with early-onset prostate cancer.  Furthermore, we observed 5 
rare, mostly private, missense variants among 4 genes (BRCA1, BRCA2, PMS2 and ATM) that 
were predicted to be deleterious and hence likely pathogenic in our patient sample. 
Conclusions: Protein-truncating mutations in BRCA2 and BRIP1 were discovered in African 
American men diagnosed with early-onset prostate cancer.  Further study is necessary to determine 
the role of rare, missense variants to prostate cancer incidence and progression in this group of 
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BACKGROUND 
Prostate cancer is the most common invasive cancer among men in the United States with 
161,360 new cases expected to be diagnosed in 2017(1). Advancing age, race and a family 
history of prostate cancer continue to be the most important predictors of risk.  The incidence of 
prostate cancer is approximately 60% higher among African American men compared to non-
Hispanic white men.   The death rate among African American men with prostate cancer is more 
than 2 times that of their non-Hispanic white counterparts. (2;3)  A number of driving factors 
have been investigated in an attempt to explain these disparities including differential access to 
and use of medical care, particularly screening for early detection and definitive treatment post-
diagnosis.(4)  The presence of comorbid conditions certainly impacts overall mortality in men 
with prostate cancer, but there is also evidence to suggest that hypertension, insulin resistance 
and abdominal obesity increase risk of disease progression after definitive treatment.  The 
prevalence of hypertension and diabetes in particular is higher in African Americans and 
symptoms are not as well controlled compared to whites.(5;6) 
 
Family history of prostate cancer, particularly among first-degree relatives, is a well-recognized 
risk factor for the disease pointing to the importance of genetics in prostate cancer risk.  It has 
been estimated that up to 40% of prostate cancers diagnosed may be attributed to one or more 
gene variants or mutations.(7)  However, the field of prostate cancer genetics has been 
challenged by both the clinical and genetic heterogeneity of the disease as well as the high rate of 
sporadic cases. Genome-wide association studies (GWAS) have resulted in the discovery of 
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polymorphisms (or SNPs) explain some of the familial clustering of disease, but in aggregate 
these variants only account for ~30% of the familial risk.(8;9)  It is unknown how many of these 
common variants are actually tagging less-common, yet highly-penetrant, coding variants.  The 
declining cost of next-generation sequencing (NGS) over the past few years has made 
sequencing coding regions of the genome a feasible strategy for the identification of rare 
mutations. 
 
As with most cancers, an earlier age at onset of prostate cancer, with or without a family history, 
is also an important indicator of the influence of inherited susceptibility.(10)  As proof, men with 
early-onset prostate cancer have been shown to have a higher likelihood of harboring disease-
associated GWAS SNPs (11) and rare mutations such as HOXB13 G84 E.(12)  Despite the fact 
that only 10% of prostate cancers in the United States are diagnosed at or before age 55 years 
(herein defined as early-onset prostate cancer), (13) there is evidence indicating that prostate 
cancer in younger men may be more clinically aggressive.  Lin et al observed among men with 
high grade and locally advanced disease, younger men tended to have a poorer prognosis 
compared to older men.(14)  We recently reported, using data from the National Cancer 
Institute’s (NCI) Surveillance, Epidemiology and End Results (SEER) program, that both 5- and 
10-year relative survival rates in men with early-onset prostate cancer were significantly worse 
compared to men in their 60s and 70s.(13)   This is particularly true of African American men 
with early-onset disease.(15)  However, our understanding of the genetic epidemiology of 
prostate cancer in African American men lags behind that of whites primarily due to low African 
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the identification and characterization of rare germline mutations in young African American 
men diagnosed with clinically significant prostate cancer.   
 
PATIENTS AND METHODS 
Eligible patients were diagnosed at 55 years of age or younger with pathologically-confirmed 
prostate cancer and self-identified as African American.  All patients were either subjects in an 
ongoing prostate cancer cohort at the Karmanos Cancer Institute (KCI) in Detroit, Michigan who 
donated DNA specimens for genetic investigation or participants of the University of Michigan 
Prostate Cancer Genetics Project (UM PCGP) in Ann Arbor, Michigan, a study founded to 
determine the genetic contribution to hereditary and early-onset prostate cancer.  Informed 
consent was obtained from each participant and protocol for each study was approved by the 
respective Institutional Review Boards.  Family history of prostate cancer among first-degree 
relatives and patient blood specimens were collected during baseline interviews for each study 




DNA was extracted from whole blood using standard protocol (Gentra® Puregene®).  Targeted 
enrichment was performed via PCR using overlapping primer sets across the exonic portions of 
the selected genes with a goal depth-of-coverage of at least 40x.  After targeted enrichment, 
samples were submitted to the University of Michigan DNA Sequencing Core for library 
preparation and NGS using HiSeq V4 (Illumina, San Diego, CA) technologies.  A commercially-
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carcinogenesis (Supplementary Table 1) (Human Comprehensive Cancer GeneRead DNASeq 
Targeted Panel V2 (Qiagen, Valencia, CA).  
 
Bioinformatics 
Analysis of data was performed using the GeneRead Targeted Exon Enrichment Panel Data 
Analysis Portal (Qiagen Inc).   Each identified variant was assessed based on the variant’s 
putative functional importance [preference given to stop/loss, frame-shifts insertions/deletions, 
important splice variants (Tier 1) followed by missense variants (Tier 2)], number of subjects 
carrying the minor allele, and observed frequency of the minor allele in publically available 
databases (e.g. ESP, dbSNP, and 1000 Genomes Project).  To determine the pathogenic potential 
of missense variants we used REVEL, an ensemble method which incorporates 18 individual 
prediction scores from 13 tools and has been shown to be particularly useful in the assessment of 
pathogenicity of rare variants.(16)  Pathogenic variants were confirmed through Sanger 
sequencing.  The number of carriers observed in our study population was reported along with 
the minor allele frequency of variants among African American samples from the Exome 
Aggregation Consortium (EXAC version 1.0, 02/27/2017).     
 
RESULTS 
Of the 96 samples selected for sequencing, 66 were from UM and 30 were from KCI.  Clinical 
characteristics of the cases are summarized in Table 1.  The median age of prostate cancer 
diagnosis of the men was 50 years (range 40 to 55 years).  The median pre-diagnosis PSA was 7 
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men were diagnosed with stage T2 disease and 9 men had either nodal or distant metastasis at 
diagnosis.   
 
We discovered samples from three African American men possessed a protein truncating 
mutation, one in the BRCA2 gene and two in the BRCA1-Interacting Protein-1 gene or BRIP1. 
Details related to the mutation, clinical characteristics and cancer family history are provided in 
Table 2.  The only truncating mutation in BRCA2 was the result of a single point mutation 
(c.1970T>A; p. L657*) in a patient diagnosed at age 48 with Gleason 7 (3+4) disease, tumor 
stage unknown, with a positive family history of breast cancer.  The two frameshift mutations in 
BRIP1 were the result of a deletion of adenine and thymine at codon 3730 (c. 3730_3731del2; p. 
M1244Vfs*5) (Case B) and an insertion of cytosine at codon 69 (c. 69insC; p.S24Vfs*44) (Case 
C).  These men were diagnosed at age 51 and 54 years, respectively.  Case B was diagnosed with 
Gleason 7 (4+3), stage T2a disease and Case C with Gleason 3+4, stage T3a disease.  Neither 
man had any reported family history of prostate, breast or ovarian cancer. 
Table 3 lists rare (minor allele frequencies (MAF) <1% in both African American and European 
American individuals in ESP), likely deleterious (based on REVEL scores >0.7) missense 
mutations occurring in a panel of 16 DNA repair genes (ATM, ATR, BRCA1, BRCA2, BRIP1, 
CHEK2, FAM175A, GEN1, MRE11A, MSH2, MSH6, NBN, PALB2, PMS2, RAD51C, and 
RAD51D).  Deleterious mutations were previously identified in these 16 genes in a study of 
germline DNA samples isolated from 692 men with metastatic prostate cancer (5% African 
American participants) by Pritchard et al.(17)  In our cohort, we found 2 mutations in ATM, and 
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DISCUSSION 
Results from the current investigation indicate the presence of deleterious mutations in both 
BRCA2 and BRIP1 among African American men diagnosed with early-onset prostate cancer.  
We also found two rare missense mutations, one each in BRCA1 and BRCA2, that were predicted 
to be pathogenic based on the in silico prediction tool REVEL.   BRCA2 mutations have been 
associated with a 2- to 6-fold increase in prostate cancer risk.(18-21)  Numerous studies have 
signaled the importance of both hereditary breast and ovarian cancer genes (BRCA1 and BRCA2) 
with prostate cancer risk predominantly in populations of Ashkenazi Jewish, Norwegian, Dutch 
and Icelandic descent.(22)  .  These two tumor suppressor genes are involved in the maintenance 
of genomic stability through their role in double-strand DNA repair and mutations in DNA repair 
genes have been linked to both early-onset and hereditary prostate cancer, as well as more 
aggressive clinical features time of diagnosis, with earlier progression to metastatic disease and 
higher prostate cancer-specific mortality.(23-28)  Moreover, BRCA1/2 mutations have also been 
connected to response to therapy in prostate cancer, in particular response to treatment with 
platinum-based chemotherapy and Poly (ADP-ribose) polymerase (PARP) inhibitors.(29;30)  
Clinical trial results suggest that BRCA2 mutation carriers with metastatic castrate resistant 
prostate cancer treated with olaparib experience high response to treatment.(31)  Based on the 
role of BRCA1 and BRCA2 in prostate cancer risk and disease progression, NCCN guidelines 
recommend prostate cancer screening beginning at age 40 for men known to harbor a mutation in 
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To our knowledge, no other investigation has sought to characterize the role of BRCA1/2 
mutations in African American men with prostate cancer, thus much of our knowledge about the 
prevalence and spectrum of mutations are derived from studies of African American women with 
breast cancer.  An estimate of the prevalence of BRCA mutations in a population of African 
Ancestry unselected for family history or early-onset cancer has yet to be determined.  However, 
studies of young African American breast cancer patients suggest that the prevalence may be 
higher than populations of European ancestry, identifying both novel founder mutations as well 
as an increase in the proportion of mutations that might be characterized as variants of unknown 
significance (VUS).(33-37)  In a recent study of African American women diagnosed with 
primary invasive breast cancer selected for familial disease or tumor characteristics indicative of 
increased genetic susceptibility, Churpek identified damaging mutations in 22% of patients, 80% 
of which were mutations in BRCA1 or 2.  Mutations were also observed in PALB2, CHEK2, 
BARD1, ATM, PTEN and TP53.(33)     
 
Far less is known of the role of BRIP1 and prostate cancer risk specifically, although the gene 
interacts with BRCA1 playing a role in DNA damage repair.(38;39) BRIP1 is implicated in 
Fanconi anemia, a rare autosomal recessive disorder, associated with an increased risk for  acute 
myeloid leukemia and other solid tumors, including breast and prostate cancer.(40-43)  In a 
recently published series of 692 men with metastatic prostate cancer, one truncating mutation in 
BRIP1 was observed.(17) Our own work identified 7 missense variants in BRIP1 among 94 
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In this study, we also discovered two germline missense variants in ATM and one in PMS2 that 
are rare and predicted to be pathogenic based on the in silico prediction tool REVEL.    The 
Ataxia Telangiectasia Mutated (ATM) is a gene with a pivotal function in cell division and DNA 
repair and thus an attractive cancer susceptibility candidate.  Prior studies have identified 
mutations in ATM in patients with prostate cancer including lethal forms of the 
disease.(17;45;46)  With the exception of BRCA2, it is the most commonly mutated DNA repair 
gene in men with lethal disease.(17;46) The PMS2 (or post-meiotic segregation 2) gene functions 
in mismatch repair and is suggested to protect against prostate cancer progression through 
promotion of apoptosis in cancer cells.(47)  It has also been shown that a reduction or loss of the 
PMS2 protein is associated with poorer differentiation of prostate tumors.(48)  
 
The current cohort represents one of the largest investigations of early-onset prostate cancer in 
African American men aimed at identifying uncommon and rare germline variants associated 
with heightened prostate cancer susceptibility.  This valuable patient resource is further enhanced 
by the enrichment of patients with a positive family history of prostate cancer, careful collection 
of family histories of prostate and other cancers, and well-characterized clinical information.  
Enrichment of patient populations with men diagnosed with early-onset and familial disease is a 
useful tool for discovery of variants.  However, the generalizability of these findings to the larger 
population of African American men with prostate cancer is questionable given the study is 
clinic- and not population-based.  Both KCI and UM are large tertiary referral hospitals, and are 
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Our results provide evidence that rare mutations in DNA repair genes are important in African 
American men diagnosed with early-onset disease.  Given the potential therapeutic benefit in 
BRCA mutation carriers in particular, screening young African American men with prostate 
cancer irrespective of their family history of breast and ovarian cancer could have a significant 
impact on long-term survival.  Further investigation in larger, population-based patient 
populations will be critical in understanding the prevalence and range of mutations in African 
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 Table 1.  Clinical Characteristics of African American Men with Early-Onset Prostate Cancer (n=96) 
 
Variable                              Number (%) [Range] 
 
Median age of diagnosis          50 years    [40-55 years] 
 
Gleason Grade 
   6          15 (15.6%) 
3+4=7             48 (50.0%) 
 4+3=7          12 (12.5%) 
>7          19 (19.8%) 
Unknown           2   (2.1%) 
 
Median PSA at diagnosis         7 ng/ml               [1.2 to 3686 ng/ml] 
 
T Stage            
T2           52 (54.2%) 
T3           18 (18.8%) 
T4            1 (1.0%) 
Unknown          25 (26%) 
 
N0/NX and M0/MX         74 (77.1%) 
M1 or N1            9 (9.4%) 
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Table 2.  Characteristics of African American Prostate Cancer Patients with Germline Protein Truncating 
Mutations 
 
                    Case A   Case B   Case C  
 
Gene     BRCA2   BRIP1   BRIP1 
GRCh37/hg19 Position  13:32910462  17:59760675  17:59938832 
Nucleotide Change  c.1970 T>A  c.3730delAT  c.69insC 
Protein Effect   Leu657Stop  Met1244ValfsTer5 Ser24ValfsTer44 
 
Characteristics 
Age at diagnosis (years)  48   51   54 
Pathologic Gleason Score 3+4=7   4+3=7   3+4=7    
Stage    Unknown  T2bN0M0  T3aN0M0 
PSA at Diagnosis (ng/ml) 6.1   9.2   3.5 
 
Family History 
Prostate Cancer   No   No   No 
Breast Cancer   Yes (first-degree) No   No 
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Table 3. Rare (MAF < 1%) germline missense variants with high predictive pathogenicity (REVEL 
>0.7) in African American patients with early-onset prostate cancer observed in genes previously 





















13 32913077 rs28897728 G A BRCA2 c.4585G>A G1529R 1 0.07 0 0.90 
17 41249297 rs55688530 G T BRCA1 c.557C>A S186Y 1 0 0.68 0.78 
7 6042124 rs116349687 A G PMS2 c.497T>C L166P 1 0 0.32 0.78 
11 108160480 rs138327406 T G ATM c.4388T>G F1463C 1 0.16 0.02 0.76 
11 108201014 rs201314561 C T ATM c.7381C>T R2461C 1 0 0.07 0.71 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
